#Cambridge #United Kingdom #Elisa #Abcam #SimpleStep Ignite

Abcam Unveils the Future of Immunoassays with SimpleStep Ignite™ ELISA

In a remarkable advancement for laboratory technology, Abcam, a leading company in antibody and assay solutions, has announced the launch of SimpleStep Ignite™ ELISA. This innovative chemiluminescent immunoassay platform significantly elevates testing capabilities for scientists and researchers who are facing increasing demands for speed and efficiency in their work.

Accelerating Results Without Sacrificing Accuracy

The SimpleStep Ignite™ ELISA is designed to provide results in just 55 minutes, making it up to six times faster than traditional colorimetric ELISAs. But speed isn't the only advantage; this new platform boasts a staggering 50 times greater sensitivity compared to its predecessors, allowing it to accurately quantify both low-abundance and high-abundance targets within a single workflow. As research timelines tighten and sample volumes become increasingly invaluable, the ability to deliver high-quality results quickly is critical.

Markus Lusser, President of Abcam, emphasized the importance of this advancement: “The pace of scientific progress is increasingly defined by how quickly researchers can turn complex data into confident decisions.” He further noted that SimpleStep Ignite™ reflects Abcam's commitment to facilitating scientific discovery by combining speed and performance in a streamlined manner.

A Streamlined Workflow for Better Data Output

The SimpleStep Ignite™ ELISA is built upon Abcam's already successful SimpleStep® technology, integrating chemiluminescent detection for improved signal strength and reduced background noise. This means researchers can expect more consistent and reproducible results, which is crucial when dealing with complex biological samples such as serum, plasma, or urine.

One of the standout features of the SimpleStep Ignite™ ELISA is its simplified workflow, which minimizes the time spent on incubation and reduces the number of required washes to a simple single wash protocol. This innovation allows researchers to quantify both high and low abundance targets using the same kit, decreasing repeat tests and conserving precious samples—valuable strides in efficiency and productivity.

Customized Solutions for Varied Research Needs

Each kit uses optimized antibody pairs to ensure reliable performance from batch to batch. This reliability is tied to the growing need for higher throughput screening and the ability to conduct studies plate by plate without compromising quality. As conveyed by Robert Zawada, Sr. Director of Product Development at PrognomiQ, “The new SimpleStep Ignite™ version delivers the broad performance range we require, allowing us to measure our samples with a streamlined approach without disrupting our established workflows.”

Availability and Future Prospects

The SimpleStep Ignite™ ELISA kits are now available, and researchers can explore the full range of offerings at Abcam's official website. As Abcam continues to push the boundaries of scientific innovation, the introduction of SimpleStep Ignite™ signifies a monumental step forward in immunoassay capabilities, empowering scientists to achieve more in an era defined by accelerated research demands.

About Abcam

Abcam operates under the philosophy that collaboration enhances scientific achievement. Being a part of the Danaher family allows Abcam to utilize cutting-edge science and technology, improving the quality of life globally by assisting approximately 750,000 researchers across 130 countries. The combination of Abcam and Danaher's innovative spirit positions them uniquely in addressing critical challenges in health and disease research.

In conclusion, the launch of SimpleStep Ignite™ ELISA marks a transformative time in laboratory testing, focusing on speed, sensitivity, and ease of use—essential factors for contemporary scientific inquiry. As research progresses, so does Abcam's commitment to providing impactful solutions tailored for the evolving landscape of biomedical research.